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A simple and reliable method to screen isolates of 
Escherichia coli and Klebsiella yneumoniae for the 
production of TEM- and SHV-derived 
extended-spectrum P-lactamases 
Kenneth S. Thomson and Christine C. Sanders 
Center for Research in Anti-Infectives and Biotechnology, Department of Medical Microbiology and 
Immunology, Creighton University School of Medicine, Omaha ,  Nebraska, USA 
Objective: To evaluate which of 24 0-lactams used in susceptibility tests best discriminated between strains of Klebsiella 
pneumoniae and Escherichia colithat produce extended spectrum P-lactamases (ESBLs) from strains that produce older, 
more familiar, plasmid-mediated p-lactamases such as TEM-I and SHV-1. 
Methods: Susceptibility to the 24 p-lactam agents was determined by agar dilution and disk diffusion methodologies, 
using 27 strains of K. pneumoniae and E. coli that produced 22 different older plasmid-mediated P-lactamases and 28 
strains that produced 17 different ESBLs. 
Results: In general, strains that produced ESBLs were intermediate or resistant t o  cefpodoxime, whereas those that 
produced other P-lactamases were susceptible to this agent. The agar dilution test exhibited 96% sensitivity and 100% 
specificity in  discriminating these two groups of organisms. The disk diffusion test exhibited 100% sensitivity and 96% 
specificity. All other p-lactam agents tested were inferior discriminators between the two groups of organisms. 
Conclusions: Agar dilution and disk diffusion tests with cefpodoxime can be used to discriminate strains of K. 
pneumoniae and E. coli that produce ESBLs from those that produce older, plasmid-mediated P-lactamases. 
Key words: extended-spectrum p-lactamase, E. coli, K. pneumoniae, laboratory detection 
I NTRO 0 UCTlO N 
In the mid-l980s, resistance to newer cephalosporins 
such as cefotaxime, ceftriaxone and ceftazidime, and 
also to the monobactam aztreonam, began to appear in 
isolates of Hebsiella pnetrmoniae and Escherichia coli, 
especially in France and Germany. The resistance was 
caused by mutations in the common TEM-1, TEM-2 
and SHV-1 P-lactamases which extended the hydro- 
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lytic spectrum of the enzymes to include these drugs. 
Since then, organisms which produce these extended 
spectrum p-lactamases (ESBLs) have spread world- 
wide. Although strains that produce ESBLs are charac- 
teristically resistant to newer cephalosporins and/or 
aztreonam, many strains producing these enzynies 
appear susceptible or intermediate to some or all of 
these agents in vitro, while expressing clinically signifi- 
cant resistance in infected patients [l-51. Such strains 
are often not recognized as producers of ESBLs, placing 
infected patients at risk of receiving inappropriate 
therapy, and also making it difficult to implement 
effective infection control measures. 
Therefore, reliable detection of ESBLs is an 
important problem facing clinical laboratories. Some 
investigators suggest that ESBL detection may be 
enhanced by monitoring susceptibility tests with 
cefiriaxone, cefotaxime, ceftazidime and aztreonam for 
characteristic slight decreases in susceptibility [1,4, 
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6-91. However, this approach is less than ideal because 
the slight decreases in susceptibility may not always be 
recognized. Another approach is to perform special 
supplementary tests such as the double disk poten- 
tiation test [4,6,7,9] or the three-dimensional test [I]. 
Such tests increase the laboratory workload and costs 
and sometimes require repeated performance to yield 
unequivocal results. The ideal screening test for the 
presence of ESBLs should be inexpensive, expedient, 
reliable and, preferably, also part of the routine suscepti- 
bility test. In an attempt to define an optimal screening 
test for ESBLs, 24 p-lactam agents were investigated by 
disk diffusion and agar dilution susceptibility tech- 
niques against a panel of 49 clinical and laboratory 
strains of Enterobacteriaceae that produced a variety of 
ESBLs and other plasmid-mediated P-lactamases. The 
aim was to id en ti^, if possible, a p-lactam agent to 
which most or all strains producing ESBLs were not 
susceptible (intermediate or resistant), but to which 
strains producing other plasmid-mediated P-lactamases 
were susceptible. 
MATERIALS AND METHODS 
Bacterial strains 
The sources of test strains are listed in the ack- 
nowledgments. The organisms were separated into 
two groups according to their P-lactamase type. All 
P-lactamase identifications were confirmed in our 
laboratory by appropriate biochemical or molecular 
procedures such as isoelectric focusing [10,11], 
substrate profile [12,13], inhibitor profile [Ill, plasmid 
isolation, recombinant DNA techniques and trans- 
formations [14]. To include a comprehensive range of 
P-lactamase types, it was necessary to include both 
clinical and laboratory strains. Group I comprised 27 
strains of E. coli and K. pneumoniae that produced the 
following ‘non-ESBL: plasmid-mediated enzymes: 
TEM-1, TEM-2, SHV-1, OXA-1, OXA-2, OXA-3, 
OXA-4, OXA-5, OXA-6, OXA-7, OHIO-I, TRC- 
1, PSE-1, PSE-2, PSE-4, CARB-4, LCR-1, SAF-1, 
HMS-1, LXA-1, ROB-I and TLE-1. This group 
included strains that hyperproduced TEM-1, TEM-2 
and SHV-1 p-lactamases. Group I1 comprised 28 strains 
of E. coli and K. pneumoniae that produced the following 
ESBLs: TEM-3, TEM-4, TEM-5, TEM-6, TEM-7, 
TEM-8, TEM-9, TEM-10, TEM-12 (TEM 101), 
TEM-16, TEM-24, TEM-26, SHV-2, SHV-3, SHV- 
4, SHV-5, SHV-6 and an unidentified ESBL ofpI 5.95. 
The quality control strains were those recom- 
mended by the National Committee for Clinical 
Laboratory Standards (NCCLS), namely Staphylococcus 
aureus ATCC 29213, S. aureus ATCC 25923, E. coli 
ATCC 25922, E. coli ATCC 35218, Pseudomonas 
aeruginosa ATCC 35218, and l? aeruginosa ATCC 27853 
[ 15,161. 
Susceptibility tests 
Antibiotic susceptibilities were determined by agar 
dilution testing with Mueller-Hinton agar (Oxoid 
CM337, Basingstoke, UK) and inoculum of lo4 CFU 
per spot [16], and by the NCCLS disk diffusion method 
[I 51. Interpretive criteria are provided in Table 1. Anti- 
microbial agents were purchased from Sigma Chemical 
Co., St Louis, MO (ampicillin, ticarcillin) or were 
kindly provided by the following companies: Pfizer 
Inc., Groton, CT (cefoperazone, sulbactam), the R. W. 
Johnson Pharmaceutical Research Institute, Raritan, 
NJ (FK-037), Pharmacia-Upjohn Co., Kalamazoo, 
MI (cefpodoxime), Hoffmann-LaRoche, Nutley, NJ 
(ceftriaxone), Eli Lilly, Indianapolis, IN (loracarbef, 
cefaclor, cefamandole, cephalothin), Glaxo Wellcome 
Inc., Research Triangle Park, NC (cefuroxime, 
ceftazidime), Merck, Sharp & Dohme, West Point, PA 
(cefoxitin, imipenem), Wyeth Ayerst Lederle, Pearl 
River, NY (piperacillin, tazobactam, cefixime), Parke- 
Davis, Ann Arbor, MI (cefdinir), Zeneca Pharma- 
ceuticals, Wilmington, DE (cefotetan, meropenem), 
Hoechst-Roussel Pharmaceuticals Inc., Somerville, NJ 
(cefotaxime), Bristol-Myers Squibb Co., Wallingford, 
CT (cefprozil, aztreonam). Antibiotic susceptibility 
disks impregnated with the above agents were either 
supplied by the manufacturer or purchased from 
Becton Dickinson, Cockeysvdle, MD. 
RESULTS 
As shown in Table 1, cefpodoxime most clearly 
discriminated strains which produced ESBLs (group 11) 
from strains producing other plasmid-mediated P- 
lactamases (group I) when NCCLS interpretive criteria 
were used. In agar dilution tests 100% of group I strains 
were susceptible to cefpodoxime, while only 4% of 
group I1 strains were susceptible (96% sensitivity, 100% 
specificity). In disk diffusion tests, 96% of group I 
strains and no group I1 strains were susceptible to 
cefpodoxime (100% sensitivity, 96% specificity). The 
only group I strain not susceptible to cefpodoxime was 
E. coli MISC 174, which produced OXA-4. The zone 
diameter of 20 mm for this strain is classified as 
intermediate by NCCLS standards. Although they did 
not achieve sufficient sensitivity to be regarded as 
reliable discriminators, the next most useful drugs were 
cefixime (89% sensitivity, 100% specificity in agar 
dilution tests; 79% sensitivity, 96% specificity in disk 
diffusion tests) and cefiazidime (82% sensitivity, 100% 
specificity in both agar dilution and disk diffusion tests). 
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Table 1 Percentage susceptibility of two groups of P-lactamase-producing members of the family Enterobacteriaceae in agar 
dilution and disk diffusion tests 
Interpretive criteria' 
Drug 
~~ ~ 
Group I 3  Group 11' Agar dilution test Disk test 
Agar ddution Disk Agar dduQon Disk 
test test test test S R S K 
Cefaclor 
Cefdinir 
Cefixime 
Cefpodoxime 
Cefprozil 
Loracarbcf 
Cephalothin 
Cefaniandole 
Cefuroxiiiie 
Cefoperazone 
Cefotaxinie 
Ceftazidime 
Ceftriaxone 
FK-037 
Cefotetan 
Cefoxitin 
Aztreonam 
Anipicillin/Sulbactani 
Piperacilliii 
Piprracillin/Tazobactam 
Ticarcillin/Clavulanate 
Iniipenem 
Meropenem 
74 
100 
100 
100 
78 
96 
59 
67 
100 
85 
100 
100 
100 
100 
100 
100 
100 
33 
41 
85 
37 
100 
100 
74 
96 
96 
96 
74 
89 
33 
56 
100 
67 
100 
100 
100 
100 
100 
100 
100 
30 
11 
56 
37 
100 
100 
50 
79 
11 
4 
25 
64 
0 
36 
57 
79 
93 
18 
93 
89 
100 
82 
46 
29 
4 
93 
14 
100 
100 
50 1 8  
57 5 1  
21 1 1  
0 1 2  
29 5 8  
75 5 8  
0 5 8  
32 5 8  
68 5 8  
32 5 16 
54 5 8  
18 5 8  
50 5 8  
71 5 8  
96 5 1 6  
93 1 8  
39 5 8  
36 I 8 / 4  
0 5 1 6  
82 5 16/4 
32 5 16/2 
100 5 4  
100 5 4  
232 
2 4  
2 4  
28 
232 
232 
232 
232 
232 
264 
264 
232 
264 
232 
264 
232 
232 
232/16 
2128 
2128/4 
212812 
216 
216 
218 
220 
219 
221 
218 
218 
218 
21s 
218 
221 
223 
218 
221 
217 
216 
218 
222 
215 
221 
221 
220 
216 
216 
5 14 
5 1 6  
1 1 5  
1 1 7  
5 1 4  
1 14 
5 14 
1 1 4  
1 1 4  
5 15 
5 14 
5 14 
5 13 
513 
5 12 
1 14 
5 15 
1 1 1  
117 
5 1 7  
1 14 
5 1 3  
513 
'Group I strains (n=27) produced the following enzymes: TEM-1, TEM-2, SHV-1, O m - 1 ,  OXA-2, OXA-3, OXA-4, CIXA-5, OXA-6. 
O M - 7 ,  OHIO-1, TRC-I, PSE-1, PSE-2, PSE-4, CARE-4, LCK-1, SAR-1, HMS-1, LXA-1, ROB-1 and TLE-I. 
'Group I1 strains (n=28) produced the following enzymes: TEM-3, TEM-4, TEM-5, TEM-6, TEM-7, TEM-8, TEM-9, TEM-10, 
TEM-12 (TEM 101), TEM-16, TEM-24, TEM-26, SHV-2, SHV-3, SHV-4, SHV-6 and unidentified extended-spectrum P-lactamase of 
'NCCLS interpretive criteria for all agents except FK-037 and cefdinir (criteria for these agents supplied by manufacturers). Agar dilution 
criteria in mg/L. Disk criteria are inhibition zone diameters in mm. S ,  susceptible; R, resistant. 
pI 5.95. 
Table 2 Cumulative percentage of strains inhibited by eight B-lactam drugs and MICso, MICyo and MIC range values 
% Strains inhibited at drug concentrationsa 
Orgatllsrn MIC' 
Drug groupb 10.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 >128 M I C d  MICsoa range 
Cefixime I 15 52 81 96 100 0.12 0.5 50.06-1 
I1 7 11 46 68 75 82 89 93 100 4 64 0.5-128 
Cefpodoxinir 1 22 81 100 0.5 1 0.1 2-1 
I1 4 18 32 57 75 93 96 100 16 64 2 to >128 
Cefuroxime I 59 100 4 8 4-8 
I1 29 57 71 75 89 89 100 8 >128 4 to >128 
Cefotaxime I 70 96 96 100 5 0.06 0.12 50.06-1 
I1 4 29 36 57 71 75 93 93 96 100 1 8 0.12-64 
Ceftazidime I 22 74 85 89 96 100 0.25 2 0.12-4 
I1 7 11 14 18 29 57 61 71 100 32 >128 1 to >128 
Ceftriaxone I 81 85 100 5 0.06 0.25 10.06-0.25 
I1 4 18 32 43 57 75 93 93 96 100 2 8 0.12-64 
FK-037 I 70 93 100 1 0.06 0.12 50.0641.25 
11 14 50 86 93 96 96 100 1 4 9.5-32 
Aztreonam I 48 74 96 100 0.12 0.25 50.06-0.5 
I1 4 7 21 29 39 46 57 64 93 93 100 16 64 0.25 to >128 
"Drug concentrations in mg/L. 
bGroups I and I1 as per footnotes for Table 1 
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Other agefits traditionally used to screen for ESBL 
production (cefotaxime, ceftriaxone and aztreonam) 
were far less suited for ESBL detection with sensitivities 
ranging from 7% to 54% in agar dilution tests and from 
46% to 61% in disk diffusion tests. 
and MIC90 values, and MIC ranges for the eight most 
promising agents. In addition to its interpretive criteria, 
the NCCLS provides an ESBL screening recom- 
mendation of 1 2  mg/L of cefotaxime, ceftriaxone, 
cefiazidime or aztreonam for E. coli and K. pneunioniae 
isolates [16]. In this study, this recommendation was 
most accurate for ceftazidime (93% sensitivity, 96% 
specificity). Although specificity was 100% for each 
drug, the sensitivity was less for aztreonam (82%), 
cefiriaxone (70%) and cefotaxime (64%). 
The NCCLS has also issued ESBL screening recom- 
mendations for disk diffusion tests with these species 
[ 151. These recommendations and their sensitivity and 
specificity for each drug in this study are as follows: 
ceftazidime 1 2 2  mm (93% sensitivity, 100% speci- 
ficity); aztreonam 5 2 7  mm (85% sensitivity, 100% 
specificity); cefiriaxone 1 2 5  mm (85% sensitivity, 100% 
specificity); cefotaxime 5 2 7  m m  (80% sensitivity, 
96% specificity). 
FK-037 discriminated the two groups in MIC 
tests, inhibiting all group I strains at 50.25 mg/L, while 
MICs of al l  group I1 strains were 21 mg/L (100% 
sensitivity and specificity). In disk tests, however, there 
was overlap between zone diameters of group I 
strains (224mm)  and group I1 strains (12-30mm). 
A zone diameter of 5 2 8  mm to discriminate group I1 
strains had 97% sensitivity and 87% specificity, while a 
criterion of 1 2 6  inm had 90% sensitivity and 93% 
specificity. 
Table 2 provides MIC distribution data, 
DISCUSSION 
The most frequently encountered clinical isolates of K. 
pneurnoniae and E. coli are represented by the strains of 
group I (producers of plasmid-mediated P-lactamases 
such as TEM-1, TEM-2 and SHV-1) and group I1 
(ESBL producers). It is vital that clinical laboratories are 
able to reliably detect ESBL production in the most 
prevalent strains, i.e. discriminate between group I and 
group I1 strains. The results of this study suggest that 
the results of cefpodoxime susceptibility tests provide 
the most reliable means of distinguishing between these 
two groups. 
The study did not include strains of E. coli and 
K. pneurnoniae that produce plasmid-mediated AmpC 
cephalosporinases. At present, such strains are only 
rarely encountered. Published reports, mostly based 
on single or small numbers of isolates that produce 
plasmid-mediated AmpC enzymes, suggest that 
cefoxitin resistance is a marker of this type of p- 
lactamase [2,17-231. If future stuhes with these types 
of strains indicate that they, like ESBL producers, are 
not susceptible to cefpodoxime, it is possible that they 
could be misclassified as ESBL producers. However, 
this interpretation should be clinically acceptable 
because it would not lead to inappropriate p-lactam 
therapy for the infected patient. From an epidemiologic 
standpoint it is desirable to distinguish between pro- 
duction of ESBLs and that of plasmid-mediated AmpC 
enzymes. This can be done using the three-dimensional 
test [1,24], but is not possible with susceptibility results 
alone, because other resistance mechanisms can yield 
similar phenotypes to AmpC enzymes. 
Isolates that are presumptively identified as ESBL- 
producing strains on the basis of susceptibility test 
results with cefpodoxime or other agents can be 
subjected to a special confirmatory test for ESBL 
detection [1,6]. In laboratories where special tests are 
not available, an interpretive comment should accom- 
pany the susceptibility results to indicate that the 
antibiogram is suggestive of ESBL production, and the 
physician should consider avoiding therapy with 
expanded-spectrum cephalosporins or aztreonam [2]. 
At present, the utility of cefpodoxime susceptibility 
tests to indicate ESBL production has only been 
demonstrated with strains of E. coli and K. pneurnoniae 
and only with disk diffusion and agar dilution pro- 
cedures. Further studies are required to evaluate this 
approach with broth dilution, automated and other 
tests and also with ESBL-producing strains belong- 
ing to other species of Enterobacteriaceae. Although 
cefpodoxime is a therapeutic agent that may not be 
routinely tested by some clinical laboratories, the results 
of this study indicate that its value as a diagnostic agent 
for ESBL detection warrants consideration. 
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